Clinical and Molecular Hepatology

Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”: Haiyu Wang, Jinjun Chen; Clin Mol Hepatol 2026;32(1):e58-e61.
Published online March 31, 2025; DOI: https://doi.org/10.3350/cmh.2025.0326

Citations

Citations to this article as recorded by

Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Mathias Jachs, Mattias Mandorfer
Clinical and Molecular Hepatology.2026; 32(1): e106. CrossRef

Refining portal hypertension assessment: The clinical significance of spleen stiffness measurement in the Baveno VII Era: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”: Do Seon Song; Clin Mol Hepatol 2026;32(1):400-402.
Published online March 24, 2025; DOI: https://doi.org/10.3350/cmh.2025.0296

Citations

Citations to this article as recorded by

Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(1): e65. CrossRef
Ammonia‐to‐Urea Ratio: A Noninvasive First‐Line Tool for Detecting Clinically Significant Portal Hypertension
Hatime Ouahbi, Vincent Haghnejad, Alexia Audouy, Maël Silva Rodriguez, Françoise Barbé, Jean‐Louis Guéant, Jean‐Pierre Bronowicki, Abderrahim Oussalah
JGH Open.2025;[Epub] CrossRef

The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study”: Haiyu Wang, Jinjun Chen; Clin Mol Hepatol 2026;32(1):403-406.
Published online March 19, 2025; DOI: https://doi.org/10.3350/cmh.2025.0274

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”: Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi; Clin Mol Hepatol 2025;31(2):e155-e157.
Published online August 30, 2024; DOI: https://doi.org/10.3350/cmh.2024.0723

Examining the therapeutic landscape of beta-blockers in portal hypertension: Anna Brujats, Càndid Villanueva; Clin Mol Hepatol 2024;30(4):1055-1059.
Published online March 6, 2024; DOI: https://doi.org/10.3350/cmh.2024.0144

Citations

Citations to this article as recorded by

Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrh
Georg Semmler, Lorenz Balcar, Mattias Mandorfer
Clinical and Molecular Hepatology.2025; 31(2): e224. CrossRef
Principles of Non-selective Beta-blocker Usage for Cirrhosis-associated Complications
Daisy K. Maclaine, Kosha J. Mehta
SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Treating onychomycosis in diabetic patients: risk, therapy, and topical opportunity
Aditya K. Gupta, Amanda Liddy, Tong Wang, Su Yong Choi, Elizabeth A. Cooper
Journal of Dermatological Treatment.2025;[Epub] CrossRef